|
1.
|
Chen J and Stubbe J: Bleomycins: towards
better therapeutics. Nat Rev Cancer. 5:102–112. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lazo JS and Humphreys CJ: Lack of
metabolism as the biochemical basis of bleomycin-induced pulmonary
toxicity. Proc Natl Acad Sci USA. 80:3064–3068. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ibrahimi OA and Anderson RR: Images in
clinical medicine. Bleomycin-induced flagellate hyperpigmentation.
N Engl J Med. 363:e362010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Xu H, Yu L, Zhang X and Wang S: Isolation,
purification and structure determination of boningmycin (Z-893). J
Chin Antibiot. 28:465–467. 2003.
|
|
5.
|
Gao N, Shang B, Zhang X, et al: Potent
antitumor actions of the new antibiotic boningmycin through
induction of apoptosis and cellular senescence. Anticancer Drugs.
22:166–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Lazo JS, Boland CJ and Schwartz PE:
Bleomycin hydrolase activity and cytotoxicity in human tumors.
Cancer Res. 42:4026–4031. 1982.PubMed/NCBI
|
|
7.
|
Schwartz DR, Homanics GE, Hoyt DG, Klein
E, Abernethy J and Lazo JS: The neutral cysteine protease bleomycin
hydrolase is essential for epidermal integrity and bleomycin
resistance. Proc Natl Acad Sci USA. 96:4680–4685. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Pei Z, Calmels TP, Creutz CE and Sebti SM:
Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin
in mammalian cells. Mol Pharmacol. 48:676–681. 1995.PubMed/NCBI
|
|
9.
|
Lazo JS, Merrill WW, Pham ET, Lynch TJ,
McCallister JD and Ingbar DH: Bleomycin hydrolase activity in
pulmonary cells. J Pharmacol Exp Ther. 231:583–588. 1984.PubMed/NCBI
|
|
10.
|
Sebti SM, Jani JP, Mistry JS, Gorelik E
and Lazo JS: Metabolic inactivation: a mechanism of human tumor
resistance to bleomycin. Cancer Res. 51:227–232. 1991.PubMed/NCBI
|
|
11.
|
Wang H and Ramotar D: Cellular resistance
to bleomycin in Saccharomyces cerevisiae is not affected by
changes in bleomycin hydrolase levels. Biochem Cell Biol.
80:789–796. 2002.PubMed/NCBI
|
|
12.
|
Einhorn LH: Curing metastatic testicular
cancer. Proc Natl Acad Sci USA. 99:4592–4595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Aouida M, Poulin R and Ramotar D: The
human carnitine transporter SLC22A16 mediates high affinity uptake
of the anticancer polyamine analogue bleomycin-A5. J Biol Chem.
285:6275–6284. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Linge A, Weinhold K, Bläsche R, Kasper M
and Barth K: Downregulation of caveolin-1 affects bleomycin-induced
growth arrest and cellular senescence in A549 cells. Int J Biochem
Cell Biol. 39:1964–1974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Linge A, Meleady P, Henry M, Clynes M,
Kasper M and Barth K: Bleomycin treatment of A549 human lung cancer
cells results in association of MGr1-Ag and caveolin-1 in lipid
rafts. Int J Biochem Cell Biol. 43:98–105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wang XM, Zhang Y, Kim HP, et al:
Caveolin-1: a critical regulator of lung fibrosis in idiopathic
pulmonary fibrosis. J Exp Med. 203:2895–2906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ferrando AA, Velasco G, Campo E and
Lopez-Otin C: Cloning and expression analysis of human bleomycin
hydrolase, a cysteine proteinase involved in chemotherapy
resistance. Cancer Res. 56:1746–1750. 1996.PubMed/NCBI
|
|
18.
|
de Haas EC, Zwart N, Meijer C, et al:
Variation in bleomycin hydrolase gene is associated with reduced
survival after chemotherapy for testicular germ cell cancer. J Clin
Oncol. 26:1817–1823. 2008.PubMed/NCBI
|
|
19.
|
Brömme D, Rossi AB, Smeekens SP, Anderson
DC and Payan DG: Human bleomycin hydrolase: molecular cloning,
sequencing, functional expression, and enzymatic characterization.
Biochemistry. 35:6706–6714. 1996.PubMed/NCBI
|
|
20.
|
Sikic B: Biochemical and cellular
determinants of bleomycin cytotoxicity. Cancer Surv. 5:81–91.
1986.PubMed/NCBI
|
|
21.
|
Sleijfer S: Bleomycin-induced pneumonitis.
Chest. 120:617–624. 2001. View Article : Google Scholar
|
|
22.
|
Simpson AB, Paul J, Graham J and Kaye SB:
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95:
a review of patients with germ cell tumours. Br J Cancer.
78:1061–1066. 1998.PubMed/NCBI
|
|
23.
|
Nagase T, Uozumi N, Ishii S, et al: A
pivotal role of cytosolic phospholipase A(2) in bleomycin-induced
pulmonary fibrosis. Nat Med. 8:480–484. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Oga T, Matsuoka T, Yao C, et al:
Prostaglandin F(2alpha) receptor signaling facilitates
bleomycin-induced pulmonary fibrosis independently of transforming
growth factor-beta. Nat Med. 15:1426–1430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Avivi-Green C, Singal M and Vogel WF:
Discoidin domain receptor 1-deficient mice are resistant to
bleomycin-induced lung fibrosis. Am J Respir Crit Care Med.
174:420–427. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Homma S, Ishii Y, Morishima Y, et al: Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Barranco SC, Haenelt BR and Gee EL:
Differential sensitivities of five rat hepatoma cell lines to
anticancer drugs. Cancer Res. 38:656–660. 1978.PubMed/NCBI
|
|
28.
|
Okamura Y, Nomoto S, Hayashi M, et al:
Identification of the bleomycin hydrolase gene as a methylated
tumor suppressor gene in hepatocellular carcinoma using a novel
triple-combination array method. Cancer Lett. 312:150–157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lazo JS, Braun ID, Labaree DC,
Schisselbauer JC, Meandzija B, Newman RA and Kennedy KA:
Characteristics of bleomycin-resistant phenotypes of human cell
sublines and circumvention of bleomycin resistance by liblomycin.
Cancer Res. 49:185–190. 1989.PubMed/NCBI
|
|
30.
|
Yen HC, Li SH, Majima HJ, et al:
Up-regulation of antioxidant enzymes and coenzyme Q(10) in a human
oral cancer cell line with acquired bleomycin resistance. Free
Radic Res. 45:707–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Belanger MM, Roussel E and Couet J:
Up-regulation of caveolin expression by cytotoxic agents in
drug-sensitive cancer cells. Anticancer Drugs. 14:281–287. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Tirado O, MacCarthy C, Fatima N, Villar J,
Mateo-Lozano S and Notario V: Caveolin-1 promotes resistance to
chemotherapy-induced apoptosis in Ewing’s sarcoma cells by
modulating PKCalpha phosphorylation. Int J Cancer. 126:426–436.
2010.PubMed/NCBI
|
|
33.
|
Parton RG and Simons K: The multiple faces
of caveolae. Nat Rev Mol Cell Biol. 8:185–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Park WY, Park JS, Cho KA, Kim DI, Ko YG,
Seo JS and Park SC: Up-regulation of caveolin attenuates epidermal
growth factor signaling in senescent cells. J Biol Chem.
275:20847–20852. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Volonte D, Zhang K, Lisanti MP and
Galbiati F: Expression of caveolin-1 induces premature cellular
senescence in primary cultures of murine fibroblasts. Mol Biol
Cell. 13:2502–2517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Dasari A, Bartholomew JN, Volonte D and
Galbiati F: Oxidative stress induces premature senescence by
stimulating caveolin-1 gene transcription through p38 mitogen
-activated protein kinase/Sp1-mediated activation of two GC-rich
promoter elements. Cancer Res. 66:10805–10814. 2006. View Article : Google Scholar
|
|
37.
|
Cho KA, Ryu SJ, Park JS, Jang IS, Ahn JS,
Kim KT and Park SC: Senescent phenotype can be reversed by
reduction of caveolin status. J Biol Chem. 278:27789–27795. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Robles SJ and Adami GR: Agents that cause
DNA double strand breaks lead to p16INK4a enrichment and
the premature senescence of normal fibroblasts. Oncogene.
16:1113–1123. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Aoshiba K, Tsuji T and Nagai A: Bleomycin
induces cellular senescence in alveolar epithelial cells. Eur
Respir J. 22:436–443. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Baus F, Gire V, Fisher D, Piette J and
Dulić V: Permanent cell cycle exit in G2 phase after DNA damage in
normal human fibroblasts. EMBO J. 22:3992–4002. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Robertson KA, Bullock HA, Xu Y, et al:
Altered expression of Ape1/ref-1 in germ cell tumors and
overexpression in NT2 cells confers resistance to bleomycin and
radiation. Cancer Res. 61:2220–2225. 2001.PubMed/NCBI
|
|
42.
|
Kamata Y, Yamamoto M, Kawakami F, Tsuboi
R, Takeda A, Ishihara K and Hibino T: Bleomycin hydrolase is
regulated biphasically in a differentiation- and cytokine-dependent
manner: relevance to atopic dermatitis. J Biol Chem. 286:8204–8212.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Kamata Y, Maejima H, Watarai A, Saito N,
Katsuoka K, Takeda A and Ishihara K: Expression of bleomycin
hydrolase in keratinization disorders. Arch Dermatol Res.
304:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Suszynska J, Tisonczyk J, Lee HG, Smith MA
and Jakubowski H: Reduced homocysteine-thiolactonase activity in
Alzheimer’s disease. J Alzheimers Dis. 19:1177–1183.
2010.PubMed/NCBI
|
|
45.
|
Towne CF, York IA, Watkin LB, Lazo JS and
Rock KL: Analysis of the role of bleomycin hydrolase in antigen
presentation and the generation of CD8 T cell responses. J Immunol.
178:6923–6930. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Kamata Y, Taniguchi A, Yamamoto M, et al:
Neutral cysteine protease bleomycin hydrolase is essential for the
breakdown of deiminated filaggrin into amino acids. J Biol Chem.
284:12829–12836. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Zimny J, Sikora M, Guranowski A and
Jakubowski H: Protective mechanisms against homocysteine toxicity:
the role of bleomycin hydrolase. J Biol Chem. 281:22485–224892.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Ratovitski T, Chighladze E, Waldron E,
Hirschhorn RR and Ross CA: Cysteine proteases bleomycin hydrolase
and cathepsin Z mediate N-terminal proteolysis and toxicity of
mutant huntingtin. J Biol Chem. 286:12578–12589. 2011. View Article : Google Scholar : PubMed/NCBI
|
